Panaxia and Neuraxpharm: First export of medical cannabis sublingual tablets to France


Ryan Allway

January 24th, 2022

News


The first-of-its-kind export is part of the companies’ participation in the French government’s program to regulate the medical cannabis industry

 

Both companies have previously issued their premium oils to patients in France

 

DÜSSELDORF, Germany and TEL AVIV, IsraelJan. 24, 2022 /PRNewswire/ — Panaxia Labs Israel Ltd. (“Panaxia Israel”), (TASE: PNAX), a global pharma company which develops, manufactures and markets progressive medical cannabis products in pharmaceutical quality, and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), announced today a first export of medical cannabis sublingual tablets from Israel to France.

 

The export is a part of a program by the French government and the French National Agency for the Safety of Medicines and Health Products (ANSM) to regulate French medical cannabis industry. It follows the issue of the companies’ premium oils to patients in France, as part of the ANSM program.

 

Dr. Dadi Segal, CEO of Panaxia Israel: “We are glad of another significant milestone in the implementation of our strategy. We are proud to be, alongside our partner, Neuraxpharm, part of the spearhead of the world’s leading cannabis key-players selected for the ANSM program. In addition, we are the only company in this program to supply medical cannabis sublingual tablets. According to our predictions, the French market is expected to become one of the most advanced medical cannabis markets in the world, which will be a remarkable growth engine for Panaxia”.

 

Dr. Pierre-Hervé Brun, General Manager of Neuraxpharm France: “It is a great achievement for us, together with our partner Panaxia, to have been selected as one of the few specialists offering medical cannabis on the French market under the ANSM program. As the only companies in the program providing medical cannabis sublingual tablets, we are able to offer our patients a variety of patient-oriented and more easy-to-use forms of presentation. Going forward, we will continue to work with Panaxia to pursue our strategy in the fast-growing medical cannabis sector and bring more in-demand dosage forms and treatments to market.”

 

The sublingual tablets, manufactured by Panaxia under EU-GMP standard, subject to strict clinical standards with the brand name Naxiva-Panaxir, will be issued to patients participating in the French prescriptions program, in hospitals and pharmacies all over France.

 

Medical cannabis sublingual tablets enable a higher level of absorption of the active substances into the bloodstream (without initial passage through the liver) and thus, contribute to the effective and rapid relief to the patient. The tablets also enable physicians to adjust a more precise treatment routine to the patients. According to their needs, the level of the dosage as well as the concentration of the active ingredients can be adjusted. In addition, it has been proved that the tablets contribute to a better response to treatment and improved patient satisfaction, mainly due to the effectiveness of the treatment, the simplicity and accuracy of the usage.

 

The ANSM program, which was launched in March 2021, includes about 3,000 patients, who are receiving medical cannabis in France for the first time. The list of indications compiled by the ANSM includes the following diseases and treatments: Cancer, certain types of Epilepsy, Multiple Sclerosis (MS), Palliative Care (treatments to improve the quality of life of patients with incurable diseases), and pain that does not respond to conventional treatment.

 

The market potential in France is very significant, considering only last year the French government approves the regulatory of the medical cannabis industry. According to the latest estimates, there are currently between 300,000 and 700,000 patients in France, who meet the criteria and may be eligible for a prescription for medical cannabis treatment.

 

About Panaxia Labs Israel
Panaxia Labs Israel, Ltd., which is traded on the Tel Aviv stock exchange (TASE: PNAX), is a global pharma company, which develops, manufactures and markets advanced medical cannabis-based products of pharmaceutical quality and the largest manufacturer of medical cannabis products in Israel. Panaxia is a pioneer in the medical cannabis market in Israel and the only company in Israel with an EU-GMP European production standard from the EU Health Authority, which is required for the commercial manufacturing and export of medical cannabis and its products to Europe. Panaxia specializes in the development, production and marketing of complex and advanced cannabis plant products, based on clinical information and a broad database of tens of thousands of patients.

 

Panaxia Israel is a subsidiary of the Panaxia Pharmaceutical Industries, which was established in 2010 by Dr. Dadi Segal (PhD), Dr. Eran Goldberg (PhD) and Adv. Assi Rotbart (LL. B), as the cannabis division of Segal Pharma Group, which has been operating for over four decades, manufacturing more than 600 different pharmaceuticals distributed in over 40 countries. The Panaxia Group has over 150 employees.

 

To learn more about Panaxia, please visit: https://panaxia.co.il.

 

About the Group Neuraxpharm
Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS) with a direct presence in 18 countries. Backed by funds advised by Permira, Neuraxpharm has a unique understanding of the CNS market built over 35 years.

 

With its focus on CNS, Neuraxpharm develops and commercializes value-added medicines, standard generics and Consumer Healthcare products, e.g. probiotics and other nutraceuticals, and is continuously striving to offer a wide range of effective, high quality and affordable CNS treatment options in Europe.

 

Present with its products in more than 50 countries, Neuraxpharm also manufactures pharmaceutical products and active pharmaceutical ingredients in its own manufacturing sites in Spain, Lesvi and Inke.

 

To learn more about Neuraxpharm, please visit: https://www.neuraxpharm.com.

For further information, please contact: [email protected]l

 

 

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading